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Abstract
Polymyalgia rheumatica (PMR) is common. The mainstay of treatment, glucocorticoids, are associated with significant 
adverse effects and many patients remain on high doses for a number of years. Little is known about the use of other, non-
pharmacological therapies as adjuncts in PMR. The PMR Cohort Study is an inception cohort study of patients diagnosed 
with PMR in primary care. This analysis presents data on the use and perceived impact of non-pharmacological therapies 
from a long-term follow-up survey. Non-pharmacological treatments were classified as either diet, exercise, or complementary 
therapies. Results are presented as adjusted means, medians, and raw counts where appropriate. One hundred and ninety-
seven participants completed the long-term follow-up questionnaire, of these 81 (41.1%) reported using non-pharmacological 
therapy. Fifty-seven people reported using a form of complementary therapy, 35 used exercise and 20 reported changing 
their diet. No individual non-pharmacological therapy appeared to be associated with long-term outcomes. The use of non-
pharmacological therapies is common amongst PMR patients, despite the paucity of evidence supporting their use. This 
suggests that people perceive a need for treatment options in addition to standard glucocorticoid regimens. Further research 
is needed to understand patients’ aims when seeking additional treatments and to strengthen the evidence base for their use 
so that patients can be guided towards effective options.
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Introduction
Polymyalgia rheumatica (PMR) is an inflammatory con-
dition, which is characterised by pain and stiffness in the 
shoulder and hip girdles, predominantly affecting those aged 
over 50 years. Additional symptoms include fatigue, fever, 
anorexia, and weight loss; often accompanied by a rise in 
inflammatory markers. PMR is a common condition, with 
a lifetime prevalence estimated to be 0.85% in the UK [1]. 
Symptoms can cause significant disability and substantially 
reduce quality of life [2, 3].
Glucocorticoid medication is the mainstay of PMR 
treatment [4]; however, prolonged use is associated with 
significant adverse effects. Most treatment regimens for 
PMR consist of an initial dose of glucocorticoids to induce 
remission, followed by a tapering regimen to minimise total 
glucocorticoid exposure. Relapses are common during the 
tapering period. Whilst there are few evidence-based addi-
tional treatment options beyond the use of steroids spar-
ing agents, such as methotrexate [5], many patients remain 
on glucocorticoid therapy for a significant length of time. 
Given the challenges of long-term glucocorticoid treatment, 
patients are often keen to explore other potential treatment 
options [6, 7]. However, studies exploring use of non-phar-
macological therapies for PMR are sparse, particularly in 
comparison to other rheumatological conditions. A recent 
systematic review into non-pharmacological therapies for 
rheumatoid arthritis included 91 randomised controlled trials 
and 9 observational studies [8]. In comparison the EULAR/
ACR PMR collaborative [9] identified just 2 studies that 
considered herbal medicine for PMR and no controlled stud-
ies into non-pharmacological therapies. Despite the paucity 
of evidence, the collaborative did recommend, “considering 
an individualised exercise programme for PMR patients,” 
although there were no studies of exercise or physiotherapy 
Rheumatology
INTERNATIONAL 
 * Jake Weddell 
 jakeweddell2@gmail.com
1 School of Medicine, Keele University, Keele, Staffordshire, 
UK
2 Haywood Academic Rheumatology Centre, Midlands 
Partnership NHS Foundation Trust, Stoke-on-Trent, UK
 Rheumatology International
1 3
for people with PMR. Given the benefits of exercise for 
maintaining muscle mass and function and reducing falls 
risk, this recommendation may be understandable, but cur-
rently there is no evidence base to support implementation 
which may prevent services being commissioned.
The PMR Cohort Study assessed the epidemiology and 
long-term outcomes of people diagnosed with PMR in pri-
mary care [10]. The aim of this analysis was to investigate 
the reported use and perceived benefit of non-pharmacolog-
ical and exercise therapies for PMR and the association of 
these therapies with long-term outcomes.
Methods
Study design
The PMR Cohort Study has been described in detail else-
where [10]. Briefly, participants were recruited from 382 GP 
practices across England, between June 2012 and June 2014. 
Eligible patients were flagged to the clinician when PMR 
was entered into their record during a consultation, using 
electronic prompts in the primary care record. Patients who 
verbally consented were sent a study pack including partici-
pant information sheet, baseline questionnaire and consent 
form. Responders to this questionnaire were followed up 
via regular self-completion questionnaire up to 24 months. 
Patients who had not withdrawn from the study at this stage 
were then sent a long-term follow-up questionnaire (LTFU) 
between January and June 2019.
Data collection
Patients were included in this analysis if they responded 
to both the baseline and the LTFU questionnaire. 197 par-
ticipants completed both the baseline and the LTFU ques-
tionnaire. Responders and non-responders to the LFTU 
questionnaire were broadly similar in terms of their soci-
odemographic and PMR characteristics at baseline, although 
responders tended to live in less deprived areas. An analysis 
of the attrition from the cohort up to 2 years has previously 
been reported [11] and attrition from the LTFU will be pub-
lished separately.
The LTFU collected information pertaining to use of non-
pharmacological treatments, and the perceived helpfulness 
of these treatments using a patient completed checklist. 
Treatments were grouped as exercise (which included an 
increase in exercise and hydrotherapy), complementary ther-
apies (which included acupuncture, Alexander technique, 
aromatherapy, herbal medicine, homeopathy, massage and, 
vitamin and mineral supplementation) and diet or weight 
loss. In addition, the questionnaire asked participants to 
record whether exercises specifically for PMR were advised 
and from whom the patient received this advice (general 
practitioner, hospital physician, or physiotherapist, with the 
option to check more than one box).
Data on PMR outcomes were extracted from baseline 
and LTFU questionnaires and included pain and stiffness 
measured by a numerical rating scale (from none 0–10 as 
bad as can be), whether the patient could lift their arms 
above their head and daily prednisolone dose. At LTFU 
participants were asked whether their PMR symptoms had 
improved since first presentation (completely recovered, 
much improved, or improved). Additionally, the number of 
relapses was extracted from the LTFU.
Statistical analysis
Non-pharmacological therapies used are presented as n (%). 
Sociodemographic data are presented as means and stand-
ard deviations, medians and interquartile ranges or n (%) 
as appropriate. Outcomes are presented as either adjusted 
means, with the related baseline variable as the adjusting 
factor, or as n (%). Adjusted means were computed using 
one-way ANCOVA and are presented with 95% confidence 
intervals. Analysis was performed using SPSS v27.
Results
Overall, 197 patients completed both questionnaires. The 
mean age at diagnosis was 72.0 (SD 8.2) and 63.5% were 
female (Table  1). Of the 197 participants, 81 (41.1%) 
reported use of a non-pharmacological treatment during 
their disease course. People reporting use of non-pharma-
cological treatments were younger (69.4 vs 73.8) and more 
likely to be female (74.1% vs 56.0%), although the base-
line symptom reporting between both groups was similar 
(Table 1).
The most utilized type of therapies was complemen-
tary therapies, which 57 respondents reported, followed by 
exercise therapies (35 users). There was significant overlap 
between groups (Fig. 1), with 19 using any two of combina-
tions of diet/exercise/complementary therapies and 6 utilis-
ing all three types. In total, 50 participants (25.4%) reported 
being advised on PMR specific exercises by a healthcare 
professional, 34 reported receiving exercises from a physi-
otherapist (17.7%), 18 from a general practitioner (9.1%) and 
12 from a hospital physician (6.1%) and some from multiple 
sources. Of the 50 participants advised on PMR specific 
exercises, only 13 (26.0%) reported utilising exercise.
The most popular non-pharmacologic therapy reported 
was massage with 29 users (14.7%), followed by change in 
exercise with 26 users (13.2%). Therapies less frequency 
utilized include Alexander technique (two users), homeopa-
thy (five users) and aromatherapy (six users). In terms of 
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perceived helpfulness, massage had the highest proportion 
who perceived it to be helpful (25/29, 86%), followed by 
change in exercise (22/26, 84.6%).
Long-term outcomes were broadly similar between 
users and non-users of non-pharmacological therapy, with 
no difference in long-term pain and stiffness scores, or 
prednisolone dosage at follow-up (Table 2). Users of non-
pharmacological therapies reported more flares (33.3% vs 
25.0%), less improvement in symptoms (71.3% vs 79.3%) 
and were less likely to report being able to raise their arms 
above their heads (79.0% vs 89.7%) compared to non-users 
at LTFU. A significant number of participants in all groups 
reported prednisolone use at LTFU although fewer users of 
non-pharmacological therapies reported using prednisolone 
(23 people (28.4%) users vs 45 (38.8%) non-users).
Discussion
Glucocorticoids remain the mainstay of treatment for PMR, 
despite adverse events associated with prolonged use. This 
study demonstrates that more than 5 years after diagnosis 
a large number of patients are still taking glucocorticoids. 
We have demonstrated that the use of non-pharmacological 
therapies in PMR is common with 41% utilising at least one 
therapy and 29% at least one complementary therapy. Many 
non-pharmacological therapies were perceived to be helpful, 
with most participants reporting change in exercise (85%), 
massage (86%) and hydrotherapy (81%) as being helpful, 
although none of the non-pharmacological therapies utilised 
were associated with significant difference in pain, stiffness 
or prednisolone dosage at LTFU; however, a cohort study 
is not the most effective at investigating such associations.
Overall, 81 out of 197 participants used at least one non-
pharmacological therapy in the management of their PMR, 
with many participants utilising more than one therapy. 
Users of non-pharmacological therapy tended to be younger 
(69 vs. 74) and more likely to be female (74% vs 56%) in 
line with the general population [12]. Compared to studies of 
people with, rheumatoid arthritis and osteoarthritis rates of 
non-pharmacological therapy use is lower (41% vs. 98% and 
99%, respectively) [10], which may reflect a better developed 
evidence base in other conditions. The demographics of the 
Table 1  Demographics and baseline features of users and non-users of non-pharmacological therapies






therapy (n = 57)
Recommended 
exercise (n = 50)
Age at diagnosis 
[mean(SD)]
73.8 (7.4) 69.4 (8.7) 68 (9.9) 70.2 (9.6) 69.7 (8.4) 70.3 (7.8)
Female [n (%)] 65 (56.0%) 60 (74.1%) 28 (80%) 15 (75.0%) 44 (77.2%) 30 (60.0%)
BMI at baseline 
[mean(SD)]
26.7 (4.1) 28.4 (6.3) 27.6 (4.1) 32.1 (8.2) 28.4 (5.9) 28.4 (6.8)
Baseline prednisolone 
dose [mean(SD)]
15.3 (8.0) 16.1 (6.9) 15.9 (7.2) 15.8(7.4) 16.3 (7.2) 15.9 (8.1)
Baseline pain NRS 
[median(IQR)]
8.0 (7.0–10.0) 8.0 (7.0–9.0) 8.0 (6.0–9.0) 8.0 (6.3–9.0) 8.0 (7.0–9.0) 8.0 (6.8–9.0)
Baseline stiffness NRS 
[median(IQR)]
8.0 (7.0–9.0) 8.0 (6.5–9.0) 7.0 (6.0–9.0) 8.0 (5.3–10.0) 8.0 (7.0–9.0) 8.0 (7.0–9.0)
Baseline morning stiff-
ness > 1 h [n (%)]
86 (74.1%) 55 (67.9%) 24 (68.6%) 13 (65.0%) 39 (68.4%) 38 (76.0%)
Fig. 1  Venn diagram showing overlap of diet, exercise and comple-
mentary therapy users with numbers representing n 
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osteoarthritis patients surveyed were similar in terms of age 
(70 vs. 72) and gender (72% vs. 64% female); however, the 
rheumatoid population were significantly younger (57 vs. 
72) and more likely to be female (80% vs. 64%), In compari-
son, research into non-pharmacological therapies for PMR is 
sparse, with just two non-randomised small scale trials into 
Chinese herbal therapies reported in the literature [13, 14].
Whilst the most commonly reported type of non-pharma-
cological therapy was complementary therapies, this was a 
combination of a variety of different interventions. Despite 
guidelines advocating exercise in PMR only 35 (17%) report 
using exercise to manage their PMR and 50 (25%) report 
receiving specific exercise advice from a clinician. Of those 
who reported using exercise to manage their PMR, 85% 
reported benefit. Although there is a gap in the evidence 
to support the use of exercise for PMR specifically, given 
its effects on increasing skeletal muscle mass and func-
tion, reducing inflammation and improving joint function 
in rheumatoid arthritis, resulting in long-term improvement 
in pain, stiffness and overall functioning [15]. Additionally, 
exercise is well known to reduce weight, improve glycaemic 
control and increase bone density, and, therefore, may coun-
teract the side effects of glucocorticoid therapy in PMR. In 
our study, there was little difference in long-term outcome 
between users and non-users of exercise therapies; however, 
interpretation is limited as data was not collected on length 
of use, exercise intensity or timing of exercise relative to 
disease onset or reporting of outcomes. The overall associa-
tion between exercise and PMR outcomes is not clear and 
requires further research.
Despite the paucity of evidence, the most recent 
EULAR guidelines recommend an “individualised exercise 
programme” should be considered for PMR patients [9]. In 
our cohort, only 50 participants (25%) were advised to per-
form PMR specific therapies by a healthcare professional, 
and of these just 13 (26%) reported undertaking a change 
in exercise. Barriers to exercise identified in rheumatoid 
arthritis patients include uncertainty over which exercises 
may be beneficial and fear that exercise may worsen joint 
health and therefore symptoms [15]. Further research into 
barriers to exercise use in PMR patients, and clinicians’ 
perspectives on exercise are needed to tailor appropriate 
patient information and improve rates of exercise use. The 
larger number of people reporting using exercise to man-
age their PMR, despite it not having been recommended 
by a health professional suggests this may be appealing 
to patients.
The reported use of physiotherapy within the cohort was 
low, with only 17.3% given exercises from a physiotherapist. 
In comparison, for adhesive capsulitis and rotator cuff tears 
in the UK, 71% and 77% of GPs refer patients to physi-
otherapy, respectively [16]. However, lack of commissioned 
pathways and local resources may be a factor in the low use 
of physiotherapy. The Chartered Society of Physiotherapy 
has highlighted increased workloads and reductions in physi-
otherapy services across the UK, with large regional dis-
parities [17]. Other barriers to physiotherapy access may 
also have a role. A study of physiotherapy referrals for hip/
knee osteoarthritis in the UK, demonstrated that only 41% 
of potentially eligible patients were recommended physi-
otherapy by their GP, and of these 17% then did not attend 
physiotherapy [18]. Given the high number of MSK comor-
bidities in PMR patients [19, 20], physiotherapists are well 
placed to provide safe, effective and individualised exercise 
Table 2  Long-term outcomes of users and non-users of non-pharmacological therapies











Follow-up pain score 
NRS [adjusted mean 
(95% CI)]
2.5 (2.0–3.0) 3.3 (2.7–4.0) 3.2 (2.3–4.1) 4.7 (3.5–5.9) 4.5 (2.8–4.2) 3.5 (2.8–4.3)
Follow-up stiffness 
NRS [adjusted mean 
(95% CI)]
2.7 (2.2–3.2) 3.7 (3.1–4.4) 3.4 (2.4–4.4) 5.3 (4.1–6.6) 3.8 (3.1–4.6) 3.9 (3.1–4.7)
Raise arms above 
head today? n (%)
104 (89.7%) 64 (79.0%) 30 (85.7%) 15 (75.0%) 45 (78.9%) 38 (76.0%)
Current use of predni-
solone, n (%)
45 (38.8%) 23 (28.4%) 12 (40%) 9 (45.0%) 11 (19.3%) 18 (36.0%)
Current prednisolone 
dose [adjusted mean 
(95%CI)]
2.7 (1.6–3.8) 1.8 (0.6–3.1) 2.0 (0.1–4.0) 1.9 (-0.8 – 4.6) 3.1 (2.2–4.1) 1.9 (0.2–3.5)
Symptom Improvement 
n (%)
92 (79.3%) 58 (71.3%) 24 (68.6%) 9 (45.0%) 41 (71.9%) 32 (64%)
Any flares, n (%) 29 (25.0%) 27 (33.3%) 11 (31.4%) 10 (50%) 20 (35.1%) 15 (30%)
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in this heterogenous patient group, therefore further research 
into the role of physiotherapy in PMR is needed.
The motivation behind the use of non-pharmacological 
therapies is complex. Research from rheumatoid arthritis 
demonstrates factors including treatment dissatisfaction, 
poor relationship with a healthcare provider, and per-
ceived benefit of alternative therapies drive their use [21]. 
In our cohort, a significant number of participants had lit-
tle improvement in stiffness or pain, suffered from disease 
relapses and remained on prednisolone at long-term follow-
up. It is unclear whether is long-term prednisolone use is 
related to exercise use and if so, whether continued need for 
glucocorticoids drives the desire for alternative treatments 
or vice versa.
Conclusion
The use of non-pharmacological therapies in patients with 
PMR is common, with many patients utilising multiple 
therapies. Exercises were used by 17% and recommended 
to just 25% of the cohort. The lack of current evidence-based 
therapies beyond glucocorticoids is detrimental to long-term 
patient outcomes and may result in dissatisfaction in overall 
care. Further research is needed to identify which non-phar-
macological therapies provide benefit to patients with PMR.
Acknowledgements This project was undertaken with the support 
of the Keele Clinical Trials Unit, Keele University, UK. The authors 
would like to thank the staff at Keele University’s Primary Care Centre 
Versus Arthritis and the staff and patients of the participating practices 
and National Institute for Health Research Clinical Research Networks. 
The PMR Cohort Study was funded by an Arthritis Research UK Cli-
nician Scientist Award to CDM (grant number 19634) and a project 
grant from Versus Arthritis (21827). CDM and SM are funded by the 
National Institute for Health Research (NIHR) Applied Research Col-
laboration (West Midlands). CDM is funded by the NIHR School for 
Primary Care Research. This article presents independent research 
funded by the National Institute for Health Research (NIHR). The 
views expressed are those of the author(s) and not necessarily those of 
the NHS, the NIHR or the Department of Health. The study funders 
had no role in the study design; data collection, analysis, or interpreta-
tion; in the writing of the paper; or in the decision to submit the paper 
for publication.
Author contributions All authors meet the ICJME 4 criteria for author-
ship. All authors made substantial contribution to the conception of 
the work, analysis and interpretation of data, drafting and revising the 
manuscript, gave final approval of the manuscript to be published and 
agree to be accountable for all aspects of the work relating to integrity 
and accuracy.
Declarations 
Conflict of interest The School of Medicine has received funding from 
Bristol Myers Squibb to support recruitment to a non-pharmacological 
study screening for atrial fibrillation.
Ethical approval For this study was received from the Staffordshire 
Research Ethics Committee (REC reference number 12/WM/0021) and 
all patients provided written informed consent. This study complies 
with the declaration of Helsinki.
Data availability Keele University is a member of the UK Reproduc-
ibility Network and committed to the principles of the UK Concordat 
on Open Research Data. The School of Medicine and Keele Clinical 
Trials Unit have a longstanding commitment to sharing data from our 
studies to improve research reproducibility and to maximise benefits for 
patients, the wider public, and the health and care system. We encour-
age collaboration with those who collected the data, to recognise and 
credit their contributions. The School of Medicine and Keele Clinical 
Trials Unit make data available to bona-fide researchers upon reason-
able request via open or restricted access through a strict controlled 
access procedure. The release of data may be subject to a data use 
agreement (DUA) between the Sponsor and the third party requesting 
the data. In the first instance, data requests and enquiries should be 
directed to medicine.datasharing@keele.ac.uk.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article's Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article's Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
References
 1. Partington RJ, Muller S, Helliwell T et al (2018) Incidence, prev-
alence and treatment burden of polymyalgia rheumatica in the 
UK over two decades: a population-based study. Ann Rheum Dis 
77:1750–1756. https:// doi. org/ 10. 1136/ annrh eumdis- 2018- 213883
 2. Hutchings A, Hollywood J, Lamping DL et al (2007) Clinical 
outcomes, quality of life, and diagnostic uncertainty in the first 
year of polymyalgia rheumatica. Arthritis Rheum 57:803–809. 
https:// doi. org/ 10. 1002/ art. 22777
 3. Twohig H, Mitchell C, Mallen C et al (2015) “I suddenly felt I’d 
aged”: a qualitative study of patient experiences of polymyalgia 
rheumatica (PMR). Patient Educ Couns 98:645–650. https:// doi. 
org/ 10. 1016/j. pec. 2014. 12. 013
 4. Hernández-Rodríguez J (2009) Treatment of polymyalgia rheu-
matica. Arch Intern Med 169:1839. https:// doi. org/ 10. 1001/ archi 
ntern med. 2009. 352
 5. Caporali R, Cimmino MA, Ferraccioli G et al (2004) Prednisone 
plus methotrexate for polymyalgia rheumatica. Ann Intern 
Med 141:493. https:// doi. org/ 10. 7326/ 0003- 4819- 141-7- 20041 
0050- 00005
 6. Morton C, Muller S, Bucknall M et al (2019) Examining manage-
ment and research priorities in patients with polymyalgia rheu-
matica: a primary care questionnaire survey. Clin Rheumatol 
38:1767–1772. https:// doi. org/ 10. 1007/ s10067- 018- 04405-0
 7. Muller S, O’Brien A, Helliwell T et al (2018) Support available 
for and perceived priorities of people with polymyalgia rheumat-
ica and giant cell arteritis: results of the PMRGCAuk members’ 
 Rheumatology International
1 3
survey 2017. Clin Rheumatol 37:3411–3418. https:// doi. org/ 10. 
1007/ s10067- 018- 4220-1
 8. Santos EJF, Duarte C, Marques A et al (2019) Effectiveness of 
non-pharmacological and non-surgical interventions for rheuma-
toid arthritis. JBI Database Syst Rev Implement Rep 17:1494–
1531. https:// doi. org/ 10. 11124/ JBISR IR-D- 18- 00020
 9. Dejaco C, Singh YP, Perel P et al (2015) 2015 Recommenda-
tions for the management of polymyalgia rheumatica: a European 
League Against Rheumatism/American College of Rheumatology 
collaborative initiative. Ann Rheum Dis 74:1799–1807. https:// 
doi. org/ 10. 1136/ annrh eumdis- 2015- 207492
 10. Muller S, Hider S, Helliwell T et al (2012) The epidemiology 
of polymyalgia rheumatica in primary care: a research protocol. 
BMC Musculoskelet Disord 13:102. https:// doi. org/ 10. 1186/ 
1471- 2474- 13- 102
 11. Muller S, Whittle R, Hider SL et al (2020) Longitudinal clusters of 
pain and stiffness in polymyalgia rheumatica: 2-year results from 
the PMR Cohort Study. Rheumatology 59:1906–1915. https:// doi. 
org/ 10. 1093/ rheum atolo gy/ kez533
 12. Frass M, Strassl RP, Friehs H et al (2012) Use and acceptance 
of complementary and alternative medicine among the general 
population and medical personnel: a systematic review. Ochsner 
J 12:45–56
 13. Fu H (2007) Clinical observation on effect of modified Yanghe 
Decoction combined with glycocorticoid for treatment of poly-
myalgia rheumatica. Chin J Integr Tradit West Med 27:894–897
 14. Wang B, Zhang BWH (2009) Clinical observation about 18 cases 
of polymyalgia rheumatica by using Biqi capsule. China J Tradit 
Chin Med Pharm 24:596–598
 15. Cooney JK, Law R-J, Matschke V et al (2011) Benefits of exercise 
in rheumatoid arthritis. J Aging Res 2011:1–14. https:// doi. org/ 
10. 4061/ 2011/ 681640
 16. Artus M, van der Windt DA, Afolabi EK et al (2017) Management 
of shoulder pain by UK general practitioners (GPs): a national 
survey. BMJ Open 7:e015711. https:// doi. org/ 10. 1136/ bmjop 
en- 2016- 015711
 17. Chartered Society of Physiotherapy (2012) Stretched to the limit
 18. Smith T, Collier TS, Smith B, Mansfield M (2019) Who seeks 
physiotherapy or exercise treatment for hip and knee osteoarthri-
tis? A cross-sectional analysis of the English Longitudinal Study 
of Ageing. Int J Rheum Dis 22:897–904. https:// doi. org/ 10. 1111/ 
1756- 185X. 13480
 19. Partington R, Muller S, Mallen CD et al (2020) Comorbidities 
in patients with polymyalgia rheumatica prior to and following 
diagnosis: a case control and cohort study. Semin Arthritis Rheum 
50:663–672. https:// doi. org/ 10. 1016/j. semar thrit. 2020. 05. 003
 20. Partington R, Helliwell T, Muller S et al (2018) Comorbidities in 
polymyalgia rheumatica: a systematic review. Arthritis Res Ther 
20:258. https:// doi. org/ 10. 1186/ s13075- 018- 1757-y
 21. Rose G (2006) Why do patients with rheumatoid arthritis use 
complementary therapies? Musculoskelet Care 4:101–115. https:// 
doi. org/ 10. 1002/ msc. 82
Publisher's Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
